Suppository treatment in ulcerative proctitis
European Journal of Inflammation · 2021-01 · 19
DOI: 10.1177/20587392211015108 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Inflammation, online erschienen am 16.06.2021. Verfasst von Yingjie Si und 3 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Research Project of Longhua Hospital in 2016, Scholar Project of Longhua hospital, National Natural Science Foundation of China.
Abstract (Originalsprache)
Ulcerative proctitis (UP) is a common form of ulcerative colitis (UC), the number of patients with UP is increasing. Suppository treatment containing mesalamine is usually the first-line choice for mild to moderate UP, here, we review the publications on mesalamine suppository in UP, to better understand its dosage, duration of therapy and adverse events in both induction and maintenance phases. We also review articles on budesonide, beclomethasone, tacrolimus, herbal medicine and acetarsol suppositories in UP, to present therapeutic strategies for patients with UP refractory to mesalamine suppository.
Förderung
- Research Project of Longhua Hospital in 2016
- Scholar Project of Longhua hospital
- National Natural Science Foundation of China
Zitieren
APA
Si, Y., Shao, L., Gao, S., & Wen, H. (2021). Suppository treatment in ulcerative proctitis. European Journal of Inflammation, 19. https://doi.org/10.1177/20587392211015108
Vancouver
Si Y, Shao L, Gao S, Wen H. Suppository treatment in ulcerative proctitis. European Journal of Inflammation. 2021;19. doi:10.1177/20587392211015108
BibTeX
@article{Si2021,
author = {Si, Yingjie and Shao, LanJun and Gao, Shanqing and Wen, Hongzhu},
title = {Suppository treatment in ulcerative proctitis},
journal = {European Journal of Inflammation},
year = {2021},
volume = {19},
doi = {10.1177/20587392211015108}
}
EUVIMED